They just presented there like 2 days ago...
...it's not beyond the realm of reality to believe that they had discussions. Afterall, speakers don't show up the day of a presentation from the East Coast. They fly in for the week, hang out, have some drinks, whatever.
Genta Incorporated (GNTA:$0.0056,$-0.0005,-8.20%) announced the presentation of a progress update on the company's ongoing Phase 3 trial of Genasense(R) (oblimersen sodium) Injection, Genta's (GNTA:$0.0056,$-0.0005,-8.20%) lead oncology product, in patients with advanced melanoma. The data were presented in conjunction with the 27th Annual JP Morgan Healthcare Conference in San Francisco, CA. AGENDA is a Phase 3, randomized, double-blind, placebo-controlled trial that is intended to support global registration of Genasense for patients with advanced melanoma. The study is designed to confirm certain safety and efficacy results from Genta's (GNTA:$0.0056,$-0.0005,-8.20%) prior randomized trial of Genasense combined with dacarbazine (DTIC) in patients who have not previously received chemotherapy and who are identified by a biomarker (low-normal levels of lactate dehydrogenase [LDH]). The co-primary endpoints of AGENDA are progression-free survival (PFS) and overall survival. To date, more than three-quarters of the expected total number of 300 patients have been randomized into AGENDA. A total of 77 sites in 12 countries are open in Europe, the U.S., Canada, and Australia.
